Swedish Cancer Institute Earns Accreditation

May 14, 2019
Swedish Cancer Institute’s (SCI) Center for Blood Disorders and Stem Cell Transplantation achieved accreditation status from the Foundation for the Accreditation of Cellular Therapy (FACT). This achievement signifies recognition of the highest quality standards guiding the practice of cellular therapy at Swedish. 

FACT accreditation puts Swedish Cancer Institute for Blood Disorders and Stem Cell Transplantation on a select list of institutions that meet the most rigorous standards in every aspect of stem cell therapy, including clinical care, donor management, cell collection, processing, storage, transportation, administration and cell release.

Swedish currently performs adult stem cell transplantation and cellular therapies including CAR-T cell therapy and works in partnership with Bloodworks Northwest, also accredited, for peripheral blood cellular therapy product collection and cellular therapy product processing with minimal manipulation.  CAR-T cell therapy is the most up-to-date, cutting edge therapy that harnesses the power of the patient’s own immune system to eradicate the disease.  

 “Our patient-centered care delivery inspires us to pursue voluntary accreditations such as this, ensuring our patients and their families are confident in our commitment to quality outcomes, said Dr. John Pagel, the chief of Hematologic Malignancies and director of Stem Cell Transplantation ”Patients at Swedish can be confident knowing they are receiving care from an institution with this distinguished designation.”

The accreditation process involves demonstration of practices aligned with FACT’s rigorous quality standards through evaluation of standard operating procedures and quality management systems via document reviews and an on-site inspection. These evidence-based standards are developed by leading cellular therapy experts and focus on improving patient outcomes.